The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial.
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000523:psychology*; D002800:Cholinesterase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D003071:Cognition / Q000187:drug effects*; D018450:Disease Progression; D004311:Double-Blind Method; D004562:Electrocardiography / Q000187:drug effects; D005260:Female; D005702:Galantamine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008134:Long-Term Care; D008297:Male; D009483:Neuropsychological Tests; D011569:Psychiatric Status Rating Scales
D002800:Cholinesterase Inhibitors; D005702:Galantamine